NASDAQ:DEPO - Depomed Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$7.18
Today's Range$7.09 - $7.42
52-Week Range$4.31 - $9.48
Volume940,193 shs
Average Volume1.30 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:DEPO
Previous Symbol
CUSIP24990810
Phone510-744-8000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees434
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable

Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed Inc (NASDAQ:DEPO) announced its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.03. The specialty pharmaceutical company earned $63.27 million during the quarter, compared to analysts' expectations of $63.72 million. The business's revenue was down 37.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.08 EPS. View Depomed's Earnings History.

What price target have analysts set for DEPO?

5 Wall Street analysts have issued 12-month target prices for Depomed's shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Depomed's stock price to reach $9.00 in the next year. View Analyst Price Targets for Depomed.

What is the consensus analysts' recommendation for Depomed?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Depomed.

Has Depomed been receiving favorable news coverage?

Press coverage about DEPO stock has trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Depomed earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:
  • Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
  • Mr. August J. Moretti, CFO & Sr. VP (Age 67)
  • Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
  • Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
  • Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)

How do I buy shares of Depomed?

Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's official website?

The official website for Depomed is http://www.depomedinc.com.

How can I contact Depomed?

Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]


MarketBeat Community Rating for Depomed (NASDAQ DEPO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  352 (Vote Underperform)
Total Votes:  804
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel